Otieno, C. F.Association of Kenya Physicians Scientific Conference (11th : Mar. 2007 : Eldoret, Kenya)2007-11-192007-11-192007https://hdl.handle.net/1805/1183Background: Largest head-to-head, double-blind study of metformin, glyburide and rosiglitazone (N = 4,360). Primary objective: To compare the durability of glycemic control using rosiglitazone versus metformin or glyburide as initial monotherapy in patients with recently diagnosed type 2 diabetes. Design: Double-blind, randomized, controlled trial. Inclusion criteria: Type 2 diabetes ≤ 3 years, drug-naive, male and female, aged 30–75 years, FPG 126–180 mg/dl (7–10 mmol/l). Exclusion criteria: Previous use of glucose-lowering therapy, women of child-bearing potential, significant hepatic disease, renal impairment, unstable or severe angina, known CHF (NYHA Class I–IV), uncontrolled hypertension. Treatment duration: Treatment period: 4 to 6 years. Median duration of treatment: 4 years (rosiglitazone and metformin); 3.3 years (glyburide). Interventions: Rosiglitazone, metformin, glyburide.entype 2 diabetesinsulinglycemic controldouble-blindrosiglitazonemetforminglyburidecongestive heart failureedemagastrointestinalADOPTDiabetes Mellitus, Type 2Diabetes Mellitus, Type 2 therapyDiabetes Mellitus, Type 2 drug therapyGlyburideMetforminSulfonylurea CompoundsrosiglitazonePresentation